PD-L1/TIGIT BsAb (Novamab Biopharmaceuticals)

PD-L1/TIGIT双特异性抗体（洛启生物）

Report date: 2023/03/01 16:29:11

Base Information

Drug NamePD-L1/TIGIT BsAb (Novamab Biopharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-T cell immunoglobulin and ITIM domains
TargetsProgrammed death-ligand 1T cell immunoglobulin and ITIM domains
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A